title: Management of the clinically positive neck in organ preservation for advanced head and neck cancer.
abstract: BACKGROUND
  To investigate clinicopathologic predictive criteria for the optimal management of neck metastases in patients with advanced head and neck cancers treated with combined chemoradiotherapy.
  
  
  METHODS
  Prospective study, 48 patients. Mean length follow-up, 23 months.
  
  
  RESULTS
  Neck stage predicted neck response to chemoradiotherapy; N3 necks showed more partial responses (P = 0.04), and N1 necks showed more complete responses (P = 0.12). Primary tumor site strongly predicted the pathologic response found on neck dissection in patients with a clinical partial response (cPR) following chemoradiotherapy. There was no difference in survival between patients with a clinical complete response (cCR) after chemoradiotherapy, and patients with a pathologic complete response (pCR) after neck dissection (P = 0.20); however, when grouped together, these patients survived longer than did patients with a pPR at neck dissection (P = 0.06).
  
  
  CONCLUSIONS
  Clinical response to induction chemotherapy is a poor predictor of ultimate neck control. Induction chemotherapy followed by chemoradiotherapy, and planned neck dissection for patients with persistent cervical lymphadenopathy, provides good regional control.
authors.affiliation: Division of Otolaryngology/Head and Neck Surgery, Stanford University School of Medicine, California 94305-5407, USA.
authors.forename: P
authors.initials: P
authors.lastname: Dagum
authors.forename: H A
authors.initials: HA
authors.lastname: Pinto
authors.forename: J P
authors.initials: JP
authors.lastname: Newman
authors.forename: J P
authors.initials: JP
authors.lastname: Higgins
authors.forename: D J
authors.initials: DJ
authors.lastname: Terris
authors.forename: D R
authors.initials: DR
authors.lastname: Goffinet
authors.forename: W E
authors.initials: WE
authors.lastname: Fee
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary*; D003131:Combined Modality Therapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome